AbbVie (ABBV) FY2026 Q3 Earnings Explained

📊 Stock Price & Market Cap

• As of the filing date, the stock was $286, already close to its 52-week high of $294.89 and well above the 52-week low of $197.38, which suggests the market has already priced in quite a bit of optimism.
• Based on the filing-date data, AbbVie's market cap was about $505.54 billion, putting it firmly in giant-company territory among large-cap drug stocks.
• TTM diluted EPS was $5.81, which works out to a trailing P/E of 49.2x. That's not cheap, so investors should watch whether profits can keep up with the stock's expectations.

Data as of 2026-11-03 (filing date) · Price: Yahoo Finance · Shares & EPS: SEC filing · Forward P/E: not available · Yahoo Finance

🏦 What Wall Street Thinks

Strong Buy 16 · Buy 7 · Hold 5 · Sell 1 · Strong Sell 0

The overall analyst consensus is “Buy”: out of 29 ratings, there are 16 Strong Buy, 7 Buy, 5 Hold, and 1 Sell. The target price range is $230 to $346, with an average target of $306.71, above the filing-date share price of $286, though this is not investment advice.

Ratings as of: 2026-11-03 · Price targets as of: 2026-11-04 · Source: stockanalysis.com

Analyst forecasts are for reference only. Historically, price targets have not been very accurate. Invest at your own risk.

💰 How Much They Made

• Revenue rose from $15.78 billion to $17.4 billion. Management said that was 10.3% growth at actual exchange rates and 10.5% growth at constant currency.
• Gross profit increased from $10.47 billion to $13.12 billion, while gross margin improved from 66% to 75%. That was mainly due to higher revenue, fixed-cost leverage, and lower amortization of intangible assets plus less impact from last year's impairment.
• Net income attributable to shareholders rebounded sharply, not only because the company sold more, but also because last year's acquisition-related R&D and impairment charges were heavier.

📊 Where the Money Went

• Selling, general and administrative expenses were $4.09 billion, up from $3.57 billion a year earlier. Management said the operating leverage from revenue growth was offset by Apogee acquisition-related integration costs, employee incentive expenses, and litigation reserves.
• R&D expenses were $2.57 billion, compared with $2.32 billion a year earlier. The company said this was to support assets across different stages of the pipeline.
• Acquired in-process research and development and milestones expenses fell from $2.68 billion to $216 million, which was one of the main reasons operating income improved so much year over year.

🏢 Business Segments

🏦 Balance Sheet

• Total assets were $147.68 billion, up from $133.96 billion at the end of the prior fiscal year, showing the balance sheet kept expanding.
• Cash and cash equivalents were $10.77 billion, up from $5.23 billion at the end of the prior fiscal year, so short-term liquidity is more abundant.
• Shareholders' equity was negative $4.58 billion, compared with negative $3.27 billion at the end of the prior fiscal year. The verified data provided here does not include total liabilities or long-term debt, so we should not fill in missing numbers on our own.

⚠️ Total assets on the books ($147.68B) are not what the company is worth. The market values AbbVie at $505.54B, 3.4× its book assets. The gap comes from things the balance sheet doesn't show: brand, technology, customer relationships and future earning power.

📈 vs. Last Quarter

• Compared with the previous quarter, revenue rose from $16.99 billion to $17.4 billion, and net income increased from $3.61 billion to $4.22 billion.
• Operating income edged down from $6.43 billion to $6.27 billion, seemingly because of fluctuations on the expense side; the MD&A did not give a specific quarter-over-quarter explanation.

📅 vs. a Year Ago

• Revenue growth was mainly driven by Skyrizi, Rinvoq, Vraylar, Botox Therapeutic, Ubrelvy, and Qulipta, with management repeatedly pointing to market share gains and market growth.
• Humira is still a drag. Revenue this quarter was $683 million, compared with $993 million a year earlier. Management said the main reason was the ongoing impact of direct biosimilar competition after patent expiry.
• One key reason operating income improved so much was that acquired in-process research and development and milestones expenses fell from $2.68 billion to $216 million, meaning last year carried a very heavy expense burden.
• The gross margin improvement also benefited from lower amortization of intangible assets and from the $847 million intangible asset impairment recorded in the same period last year.
• The effective tax rate fell from 74% a year ago to 13%, mainly because the impact of business development activities and changes in the fair value of contingent consideration decreased, management said.

🎯 Key Takeaways for Investors

📄 Original Filing

• Original 10-Q on SEC EDGAR (2026-11-03, accession 0001551152-26-000037)
• SEC filing index (incl. financial statements)

← All AbbVie earnings reports